Pressmeddelanden

2 oktober, 2024 Icke-regulatoriskt

AcuCort granted extended SME status by the European Medicines Agency (EMA)

17 september, 2024 Icke-regulatoriskt

Zeqmelit® Launched in Norway and Finland

9 september, 2024 Icke-regulatoriskt

AcuCort Presents Study Results at the ISPOR Scientific Conference in Barcelona

2 september, 2024 Icke-regulatoriskt

Launch of Zeqmelit® Initiated – Now Available at Pharmacies

8 augusti, 2024 Icke-regulatoriskt

AcuCort’s drug Zeqmelit® registered as a trademark in the USA

1 juli, 2024 Icke-regulatoriskt

Zeqmelit® Planned to be Available in Pharmacies Starting September 1

11 juni, 2024 Icke-regulatoriskt

Very High Willingness to Pay for Zeqmelit® According to Publication in International Scientific Journal

21 maj, 2024 Icke-regulatoriskt

Study on Patients' Willingness to Pay Published in an International Scientific Journal

13 maj, 2024 Icke-regulatoriskt

The patient study on Zeqmelit® is fully recruited

17 april, 2024 Regulatoriskt

AcuCort publishes the annual report for 2023

16 april, 2024 Icke-regulatoriskt

Update on Phase IV Study: 40 of 50 Patients Recruited

26 mars, 2024 Icke-regulatoriskt

AcuCort's study to be published in an international scientific journal

20 mars, 2024 Icke-regulatoriskt

Update on Phase 4 Study: 25 Patients Recruited

11 mars, 2024 Regulatoriskt

Insider trading in subscription option TO1 - CEO Jonas Jönmark increases his stake in AcuCort AB

7 mars, 2024 Icke-regulatoriskt

Update on AcuCort's FDA Application ahead of Launch in the USA

28 februari, 2024 Icke-regulatoriskt

Newsletter focusing on the sales launch of Zeqmelit®

28 februari, 2024 Icke-regulatoriskt

AcuCort presents at three events for investors

27 februari, 2024 Regulatoriskt

AcuCort receives its first order of Zeqmelit®

16 februari, 2024 Icke-regulatoriskt

Summary: Q4 and FY 2023

13 februari, 2024 Icke-regulatoriskt

AcuCort Update on Phase 4 Study: 10 Patients Recruited

1 februari, 2024 Icke-regulatoriskt

AcuCort presents at Invest Live: Update on the process leading up to the launch of Zeqmelit®

31 januari, 2024 Regulatoriskt

First patient using Zeqmelit® in study ahead of market launch

29 januari, 2024 Icke-regulatoriskt

AcuCort receives trademark protection for Zeqmelit® in Switzerland

26 januari, 2024 Icke-regulatoriskt

AcuCort obtains trademark protection for Zeqmelit® in India